Stay updated on GSK2857916 Dose Escalation Clinical Trial

Sign up to get notified when there's something new on the GSK2857916 Dose Escalation Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the GSK2857916 Dose Escalation Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:51:35.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a potential update in the clinical trial study involving GSK2857916 for subjects with multiple myeloma and lymphomas expressing B cell maturation antigen (BCMA). This change may reflect new data or developments in the safety, pharmacokinetics, pharmacodynamics, and clinical activity testing of the antibody drug conjugate.
    Difference
    0.1%
    Check dated 2024-06-06T14:35:46.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for study participants, specifying requirements such as informed consent, age, health conditions, and prior treatments. Previously, this section indicated that no information was provided.
    Difference
    48%
    Check dated 2024-05-22T21:37:57.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:50:57.000Z thumbnail image

Stay in the know with updates to GSK2857916 Dose Escalation Clinical Trial

Enter your email address, and we'll notify you when there's something new on the GSK2857916 Dose Escalation Clinical Trial page.